- Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
- Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
- Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
- Pulse Biosciences, Inc. Announces Commencement of Rights Offering
- Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
- Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
- Pulse Biosciences Enhances Executive Leadership Team
- Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
- Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
- Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
More ▼
Key statistics
On Tuesday, Pulse Biosciences Inc (PLSE:NAQ) closed at 17.45, -14.62% below its 52-week high of 20.44, set on Jul 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.64 |
---|---|
High | 17.49 |
Low | 16.12 |
Bid | 16.45 |
Offer | 18.45 |
Previous close | 17.45 |
Average volume | 268.77k |
---|---|
Shares outstanding | 61.23m |
Free float | 17.04m |
P/E (TTM) | -- |
Market cap | 1.07bn USD |
EPS (TTM) | -0.8152 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 21:00 BST.
More ▼